VIDEO: Trial shows combo therapy benefit in metastatic castration-resistant prostate cancer
In this video, Tanya Dorff, MD, head of the genitourinary cancers program at City of Hope, discusses data presented from the TALAPRO-2 trial, presented at ASCO Genitourinary Cancers Symposium.
Dorff goes in-depth on the data from the trial, which studied the combination of poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib (Talzenna, Pfizer) and enzalutamide (Xtandi; Astellas, Pfizer) in an unselected population of patients with metastatic castration-resistant prostate cancer (mCRPC).
“Patients who have homologous combination repair alterations derive tremendous benefit from the PARP inhibitor and, in the case of these studies, from the combination of the PARP inhibitor with the [androgen-receptor]-targeted agent in the first line mCRPC space,” Dorff said.
Reference:
- Agarwal N, et al. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Presented at: ASCO Genitourinary Cancers Symposium, Feb. 16-18, 2023; San Francisco.
Collapse
Read more about